<DOC>
	<DOCNO>NCT02110082</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability maximum tolerate dose Urelumab combination Cetuximab patient Advanced/Metastatic Colorectal Cancer Advanced/Metastatic Squamous Cell Carcinoma Head Neck .</brief_summary>
	<brief_title>Combination Study Urelumab Cetuximab Patients With Advanced/Metastatic Colorectal Cancer Advanced/Metastatic Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects advanced/metastatic Colorectal Cancer ( CRC ) fail intolerant irinotecan oxaliplatin base regimen Subjects advanced/metastatic Squamous cell carcinoma head neck ( SCCHN ) without option curative treatment Subjects must measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion Men woman 18 old Women childbearing potential ( WOCBP ) men must use highly effective method contraception Eastern Cooperative Oncology Group ( ECOG ) 0 1 Subjects must life expectancy least 3 month Active progress brain metastasis Other concomitant malignancy ( exception per protocol ) Nasopharyngeal carcinoma Active history autoimmune disease Positive test Human Immunodeficiency Virus ( HIV ) 1 &amp; 2 known AIDS History hepatitis ( A , B C ) Known current drug alcohol abuse Active Tuberculosis ( TB ) Use anticancer treatment within 28 day Prior therapy antiCD137 antibody Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>